Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.

Kiavue N, Cabel L, Melaabi S, Bataillon G, Callens C, Lerebours F, Pierga JY, Bidard FC.

Oncogene. 2019 Sep 13. doi: 10.1038/s41388-019-1001-5. [Epub ahead of print] Review.

PMID:
31519989
2.

A RID-like putative cytosine methyltransferase homologue controls sexual development in the fungus Podospora anserina.

Grognet P, Timpano H, Carlier F, Aït-Benkhali J, Berteaux-Lecellier V, Debuchy R, Bidard F, Malagnac F.

PLoS Genet. 2019 Aug 14;15(8):e1008086. doi: 10.1371/journal.pgen.1008086. eCollection 2019 Aug.

3.

Circulating Tumor Cells in Early Breast Cancer.

Thery L, Meddis A, Cabel L, Proudhon C, Latouche A, Pierga JY, Bidard FC.

JNCI Cancer Spectr. 2019 Apr 27;3(2):pkz026. doi: 10.1093/jncics/pkz026. eCollection 2019 Jun.

4.

ESR1 mutations: a new biomarker in breast cancer.

Carausu M, Bidard FC, Callens C, Melaabi S, Jeannot E, Pierga JY, Cabel L.

Expert Rev Mol Diagn. 2019 Jul;19(7):599-611. doi: 10.1080/14737159.2019.1631799. Epub 2019 Jun 19.

PMID:
31188645
5.

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.

Bidard FC, Kiavue N, Ychou M, Cabel L, Stern MH, Madic J, Saliou A, Rampanou A, Decraene C, Bouché O, Rivoire M, Ghiringhelli F, Francois E, Guimbaud R, Mineur L, Khemissa-Akouz F, Mazard T, Moussata D, Proudhon C, Pierga JY, Stanbury T, Thézenas S, Mariani P.

Cells. 2019 May 28;8(6). pii: E516. doi: 10.3390/cells8060516.

6.

Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients.

Cabel L, Decraene C, Bieche I, Pierga JY, Bennamoun M, Fuks D, Ferraz JM, Lefevre M, Baulande S, Bernard V, Vacher S, Mariani P, Proudhon C, Bidard FC, Louvet C.

Cancers (Basel). 2019 Mar 21;11(3). pii: E396. doi: 10.3390/cancers11030396.

7.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K.

Crit Rev Oncol Hematol. 2019 Feb;134:39-45. doi: 10.1016/j.critrevonc.2018.12.004. Epub 2018 Dec 19. Review.

PMID:
30771872
8.

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial.

Bernard-Tessier A, Jeannot E, Guenat D, Debernardi A, Michel M, Proudhon C, Vincent-Salomon A, Bièche I, Pierga JY, Buecher B, Meurisse A, François É, Cohen R, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Borg C, Bidard FC, Kim S.

Clin Cancer Res. 2019 Apr 1;25(7):2109-2115. doi: 10.1158/1078-0432.CCR-18-2984. Epub 2018 Nov 30.

PMID:
30504426
9.

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions.

Decraene C, Bortolini Silveira A, Michel M, Bidard FC, Pierga JY, Stern MH, Proudhon C.

J Vis Exp. 2018 Sep 25;(139). doi: 10.3791/58051.

PMID:
30320738
10.

Disseminated Tumor Cells Predict Efficacy of Regional Nodal Irradiation in Early Stage Breast Cancer.

Mignot F, Loirat D, Dureau S, Bataillon G, Caly M, Vincent-Salomon A, Berger F, Fourquet A, Pierga JY, Kirova YM, Bidard FC.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):389-396. doi: 10.1016/j.ijrobp.2018.09.033. Epub 2018 Oct 4.

PMID:
30291993
11.

[Circulating tumour DNA: Current detection methods, use in radiotherapy and future development].

Castelli J, Cabel L, Bidard FC, Duvergé L, Bachet JB.

Cancer Radiother. 2018 Oct;22(6-7):653-659. doi: 10.1016/j.canrad.2018.06.018. Epub 2018 Aug 18. Review. French.

PMID:
30131269
12.

Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.

Cabel L, Jeannot E, Bieche I, Vacher S, Callens C, Bazire L, Morel A, Bernard-Tessier A, Chemlali W, Schnitzler A, Lièvre A, Otz J, Minsat M, Vincent-Salomon A, Pierga JY, Buecher B, Mariani P, Proudhon C, Bidard FC, Cacheux W.

Clin Cancer Res. 2018 Nov 15;24(22):5767-5771. doi: 10.1158/1078-0432.CCR-18-0922. Epub 2018 Jul 27.

PMID:
30054279
13.

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.

Cabel L, Proudhon C, Romano E, Girard N, Lantz O, Stern MH, Pierga JY, Bidard FC.

Nat Rev Clin Oncol. 2018 Oct;15(10):639-650. doi: 10.1038/s41571-018-0074-3. Review.

PMID:
30050094
14.

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer.

Tanguy ML, Cabel L, Berger F, Pierga JY, Savignoni A, Bidard FC.

NPJ Breast Cancer. 2018 Jun 26;4:14. doi: 10.1038/s41523-018-0068-4. eCollection 2018. Review.

15.

Correction to: Proximity ligation scaffolding and comparison of two Trichoderma reesei strains genomes.

Jourdier E, Baudry L, Poggi-Parodi D, Vicq Y, Koszul R, Margeot A, Marbouty M, Bidard F.

Biotechnol Biofuels. 2018 Jun 13;11:163. doi: 10.1186/s13068-018-1161-5. eCollection 2018.

16.

Correction to: Genome and transcriptome of the natural isopropanol producer Clostridium beijerinckii DSM6423.

de Gérando HM, Wasels F, Bisson A, Clement B, Bidard F, Jourdier E, López-Contreras AM, Ferreira NL.

BMC Genomics. 2018 Jun 1;19(1):423. doi: 10.1186/s12864-018-4799-2.

17.

Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors.

Rodrigues M, Mobuchon L, Houy A, Fiévet A, Gardrat S, Barnhill RL, Popova T, Servois V, Rampanou A, Mouton A, Dayot S, Raynal V, Galut M, Putterman M, Tick S, Cassoux N, Roman-Roman S, Bidard FC, Lantz O, Mariani P, Piperno-Neumann S, Stern MH.

Nat Commun. 2018 May 14;9(1):1866. doi: 10.1038/s41467-018-04322-5.

18.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS.

Ann Oncol. 2018 Nov 1;29(11):2268. doi: 10.1093/annonc/mdx804. No abstract available.

PMID:
29718117
19.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
20.

Genome and transcriptome of the natural isopropanol producer Clostridium beijerinckii DSM6423.

Máté de Gérando H, Wasels F, Bisson A, Clement B, Bidard F, Jourdier E, López-Contreras AM, Lopes Ferreira N.

BMC Genomics. 2018 Apr 10;19(1):242. doi: 10.1186/s12864-018-4636-7. Erratum in: BMC Genomics. 2018 Jun 1;19(1):423.

21.

Circulating tumor DNA detection in hepatocellular carcinoma.

Cabel L, Proudhon C, Buecher B, Pierga JY, Bidard FC.

Ann Oncol. 2018 May 1;29(5):1094-1096. doi: 10.1093/annonc/mdy111. No abstract available.

PMID:
29635453
22.

Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR.

Decraene C, Silveira AB, Bidard FC, Vallée A, Michel M, Melaabi S, Vincent-Salomon A, Saliou A, Houy A, Milder M, Lantz O, Ychou M, Denis MG, Pierga JY, Stern MH, Proudhon C.

Clin Chem. 2018 Feb;64(2):317-328. doi: 10.1373/clinchem.2017.272518. Epub 2017 Nov 9.

23.

Genome sequencing and transcriptome analysis of Trichoderma reesei QM9978 strain reveals a distal chromosome translocation to be responsible for loss of vib1 expression and loss of cellulase induction.

Ivanova C, Ramoni J, Aouam T, Frischmann A, Seiboth B, Baker SE, Le Crom S, Lemoine S, Margeot A, Bidard F.

Biotechnol Biofuels. 2017 Sep 7;10:209. doi: 10.1186/s13068-017-0897-7. eCollection 2017.

24.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).

Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C.

BMC Cancer. 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0.

25.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis.

Gortais H, Daniel C, Bidard FC, Jeannot E, Callens C, Cabel L.

J Thorac Oncol. 2017 Sep;12(9):e138-e139. doi: 10.1016/j.jtho.2017.04.022. No abstract available.

26.

Circulating tumor cell count and thrombosis in metastatic breast cancer.

Beinse G, Berger F, Cottu P, Dujaric ME, Kriegel I, Guilhaume MN, Diéras V, Cabel L, Pierga JY, Bidard FC.

J Thromb Haemost. 2017 Oct;15(10):1981-1988. doi: 10.1111/jth.13792. Epub 2017 Sep 1.

27.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Massard C, Borget I, Farace F, Aspeslagh S, Le Deley MC, Le Tourneau C, Bidard FC, Pierga JY, Dieras V, Hofman P, Spano JP, Ferte C, Lacroix L, Soria JC.

Eur J Cancer. 2017 Sep;83:185-193. doi: 10.1016/j.ejca.2017.05.016. Epub 2017 Jul 22.

PMID:
28743036
28.

HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report.

Cabel L, Bidard FC, Servois V, Cacheux W, Mariani P, Romano E, Minsat M, Bieche I, Farkhondeh F, Jeannot E, Buecher B.

Int J Cancer. 2017 Oct 15;141(8):1667-1670. doi: 10.1002/ijc.30863. Epub 2017 Jul 12.

29.

Proximity ligation scaffolding and comparison of two Trichoderma reesei strains genomes.

Jourdier E, Baudry L, Poggi-Parodi D, Vicq Y, Koszul R, Margeot A, Marbouty M, Bidard F.

Biotechnol Biofuels. 2017 Jun 12;10:151. doi: 10.1186/s13068-017-0837-6. eCollection 2017. Erratum in: Biotechnol Biofuels. 2018 Jun 13;11:163.

30.

Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.

Cabel L, Riva F, Servois V, Livartowski A, Daniel C, Rampanou A, Lantz O, Romano E, Milder M, Buecher B, Piperno-Neumann S, Bernard V, Baulande S, Bieche I, Pierga JY, Proudhon C, Bidard FC.

Ann Oncol. 2017 Aug 1;28(8):1996-2001. doi: 10.1093/annonc/mdx212.

PMID:
28459943
31.

Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.

Ng CKY, Bidard FC, Piscuoglio S, Geyer FC, Lim RS, de Bruijn I, Shen R, Pareja F, Berman SH, Wang L, Pierga JY, Vincent-Salomon A, Viale A, Norton L, Sigal B, Weigelt B, Cottu P, Reis-Filho JS.

Clin Cancer Res. 2017 Aug 1;23(15):4402-4415. doi: 10.1158/1078-0432.CCR-16-3115. Epub 2017 Mar 28.

32.

First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.

Dieras V, Pop S, Berger F, Dujaric ME, Beuzeboc P, Escalup L, Bidard FC, Cottu PH, LE Tourneau C, Piperno-Neumann S, Laurence V, Robain M, Asselain B, Pierga JY.

Anticancer Res. 2017 Mar;37(3):1403-1407.

PMID:
28314310
33.

Circulating tumor cells: clinical validity and utility.

Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY, Bidard FC.

Int J Clin Oncol. 2017 Jun;22(3):421-430. doi: 10.1007/s10147-017-1105-2. Epub 2017 Feb 25. Review.

PMID:
28238187
34.

Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?

Cabel L, Proudhon C, Mariani P, Tzanis D, Beinse G, Bieche I, Pierga JY, Bidard FC.

Eur J Surg Oncol. 2017 May;43(5):949-962. doi: 10.1016/j.ejso.2017.01.010. Epub 2017 Jan 29. Review.

PMID:
28185687
35.

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.

Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, Lerebours F, Bachelot T, Kerbrat P, Campone M, Eymard JC, Mouret-Reynier MA, Gligorov J, Hardy-Bessard AC, Lortholary A, Soulie P, Boher JM, Proudhon C, Charafe-Jaufret E, Lemonnier J, Bertucci F, Viens P.

Ann Oncol. 2017 Jan 1;28(1):103-109. doi: 10.1093/annonc/mdw535.

PMID:
28177480
36.

Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Riva F, Bidard FC, Houy A, Saliou A, Madic J, Rampanou A, Hego C, Milder M, Cottu P, Sablin MP, Vincent-Salomon A, Lantz O, Stern MH, Proudhon C, Pierga JY.

Clin Chem. 2017 Mar;63(3):691-699. doi: 10.1373/clinchem.2016.262337. Epub 2017 Jan 10.

37.

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.

Rochefort P, Chabaud S, Pierga JY, Tredan O, Brain E, Bidard FC, Schiffler C, Polena H, Khalil-Mgharbel A, Vilgrain I, Bachelot T.

Br J Cancer. 2017 Jan;116(3):356-361. doi: 10.1038/bjc.2016.427. Epub 2017 Jan 5.

38.

FISH-in-CHIPS: A Microfluidic Platform for Molecular Typing of Cancer Cells.

Perez-Toralla K, Mottet G, Tulukcuoglu-Guneri E, Champ J, Bidard FC, Pierga JY, Klijanienko J, Draskovic I, Malaquin L, Viovy JL, Descroix S.

Methods Mol Biol. 2017;1547:211-220. doi: 10.1007/978-1-4939-6734-6_16.

PMID:
28044298
39.

[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]].

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Llorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG).

Bull Cancer. 2016 Nov;103(11):951-952. doi: 10.1016/j.bulcan.2016.10.009. Epub 2016 Oct 28. French. No abstract available.

PMID:
28029350
40.

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.

Deniziaut G, Tille JC, Bidard FC, Vacher S, Schnitzler A, Chemlali W, Trémoulet L, Fuhrmann L, Cottu P, Rouzier R, Bièche I, Vincent-Salomon A.

Oncotarget. 2016 Nov 8;7(45):73337-73346. doi: 10.18632/oncotarget.11819.

41.

[Breast cancer screening: On our way to the future].

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Llorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG).

Bull Cancer. 2016 Sep;103(9):753-63. doi: 10.1016/j.bulcan.2016.06.005. Epub 2016 Jul 26. Review. French.

PMID:
27473920
42.

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.

Bonsang-Kitzis H, Chaltier L, Belin L, Savignoni A, Rouzier R, Hamy AS, Sablin MP, Lerebours F, Bidard FC, Cottu P, Sastre-Garau X, Laé M, Pierga JY, Reyal F.

PLoS One. 2016 Jul 7;11(7):e0159123. doi: 10.1371/journal.pone.0159123. eCollection 2016.

43.

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L'Haridon T, Cottu P, Abadie-Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges N, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Gonçalves A.

Ann Oncol. 2016 May;27(5):812-8. doi: 10.1093/annonc/mdw067. Epub 2016 Feb 18.

PMID:
27052658
44.

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

Bertucci F, Fekih M, Autret A, Petit T, Dalenc F, Levy C, Romieu G, Bonneterre J, Ferrero JM, Kerbrat P, Soulie P, Mouret-Reynier MA, Bachelot T, Lerebours F, Eymard JC, Deblock M, Lortholary A, Hardy-Bessard AC, Barthelemy P, Bonnefoi H, Charafe-Jauffret E, Bidard FC, Viens P, Lemonnier J, Pierga JY.

Lancet Oncol. 2016 May;17(5):600-11. doi: 10.1016/S1470-2045(16)00011-5. Epub 2016 Mar 28.

PMID:
27032301
45.

The Genomic Landscape of Male Breast Cancers.

Piscuoglio S, Ng CK, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC, Bidard FC, Berman S, Fusco N, Sakr RA, Eberle CA, De Mattos-Arruda L, Macedo GS, Akram M, Baslan T, Hicks JB, King TA, Brogi E, Norton L, Weigelt B, Hudis CA, Reis-Filho JS.

Clin Cancer Res. 2016 Aug 15;22(16):4045-56. doi: 10.1158/1078-0432.CCR-15-2840. Epub 2016 Mar 9.

46.

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.

Piperno-Neumann S, Diallo A, Etienne-Grimaldi MC, Bidard FC, Rodrigues M, Plancher C, Mariani P, Cassoux N, Decaudin D, Asselain B, Servois V.

Oncologist. 2016 Mar;21(3):281-2. doi: 10.1634/theoncologist.2015-0501. Epub 2016 Feb 24.

47.

Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.

Riva F, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, Stern MH, Lantz O, Proudhon C, Pierga JY, Bidard FC.

Mol Oncol. 2016 Mar;10(3):481-93. doi: 10.1016/j.molonc.2016.01.006. Epub 2016 Jan 22. Review.

48.

Circulating tumor cells in breast cancer.

Bidard FC, Proudhon C, Pierga JY.

Mol Oncol. 2016 Mar;10(3):418-30. doi: 10.1016/j.molonc.2016.01.001. Epub 2016 Jan 12. Review.

49.

Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer.

Janni WJ, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, Hall C, de Groot MR, Bidard FC, Friedl TW, Fasching PA, Brucker SY, Pantel K, Lucci A.

Clin Cancer Res. 2016 May 15;22(10):2583-93. doi: 10.1158/1078-0432.CCR-15-1603. Epub 2016 Jan 5.

50.

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.

Bonsang-Kitzis H, Chaltier L, Belin L, Savignoni A, Rouzier R, Sablin MP, Lerebours F, Bidard FC, Cottu P, Sastre-Garau X, Laé M, Pierga JY, Reyal F.

PLoS One. 2015 Dec 18;10(12):e0144359. doi: 10.1371/journal.pone.0144359. eCollection 2015. Erratum in: PLoS One. 2016;11(7):e0159123.

Supplemental Content

Loading ...
Support Center